CO6811862A2 - Métodos para tratar esclerosis múltiple y preservar y/o aumentar el contenido de mielina - Google Patents

Métodos para tratar esclerosis múltiple y preservar y/o aumentar el contenido de mielina

Info

Publication number
CO6811862A2
CO6811862A2 CO13277997A CO13277997A CO6811862A2 CO 6811862 A2 CO6811862 A2 CO 6811862A2 CO 13277997 A CO13277997 A CO 13277997A CO 13277997 A CO13277997 A CO 13277997A CO 6811862 A2 CO6811862 A2 CO 6811862A2
Authority
CO
Colombia
Prior art keywords
preserve
methods
multiple sclerosis
treat multiple
myelin content
Prior art date
Application number
CO13277997A
Other languages
English (en)
Spanish (es)
Inventor
Katherine Dawson
Neil Gilmore O
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6811862(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of CO6811862A2 publication Critical patent/CO6811862A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO13277997A 2011-05-26 2013-11-26 Métodos para tratar esclerosis múltiple y preservar y/o aumentar el contenido de mielina CO6811862A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
CO6811862A2 true CO6811862A2 (es) 2013-12-16

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13277997A CO6811862A2 (es) 2011-05-26 2013-11-26 Métodos para tratar esclerosis múltiple y preservar y/o aumentar el contenido de mielina

Country Status (19)

Country Link
US (1) US20140163100A1 (enExample)
EP (1) EP2713724A4 (enExample)
JP (1) JP2014515373A (enExample)
KR (1) KR20140036257A (enExample)
CN (1) CN103732062A (enExample)
AU (1) AU2012258558A1 (enExample)
BR (1) BR112013030169A2 (enExample)
CA (1) CA2836480A1 (enExample)
CL (1) CL2013003358A1 (enExample)
CO (1) CO6811862A2 (enExample)
EA (1) EA201391578A1 (enExample)
EC (1) ECSP13013117A (enExample)
IL (1) IL229448A0 (enExample)
MX (1) MX2013013781A (enExample)
PE (1) PE20141316A1 (enExample)
PH (1) PH12013502443A1 (enExample)
SG (1) SG195049A1 (enExample)
WO (1) WO2012162669A1 (enExample)
ZA (1) ZA201308681B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
MX355421B (es) 2011-06-08 2018-04-18 Biogen Ma Inc Proceso para preparar fumarato de dimetilo cristalino y de alta pureza.
WO2014031901A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP3566701A1 (en) 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
UA116648C2 (uk) 2013-03-14 2018-04-25 Алкермес Фарма Айерленд Лімітед Фумарати як проліки та їх застосування при лікуванні різних захворювань
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3212626B1 (en) * 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
AU2015359346B2 (en) 2014-12-11 2020-05-07 Laboratoires Juvise Pharmaceuticals Dosing regimen for a selective S1P1 receptor agonist
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1951206A1 (en) * 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
PT2137537E (pt) * 2007-02-08 2013-08-22 Biogen Idec Inc Composições e respectivas utilizações para o tratamento da esclerose múltipla
RU2554347C2 (ru) * 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
NZ617130A (en) * 2009-04-29 2015-06-26 Biogen Ma Inc Treatment of neurodegeneration and neuroinflammation

Also Published As

Publication number Publication date
CA2836480A1 (en) 2012-11-29
WO2012162669A1 (en) 2012-11-29
JP2014515373A (ja) 2014-06-30
BR112013030169A2 (pt) 2016-08-09
ZA201308681B (en) 2017-11-29
AU2012258558A1 (en) 2013-05-02
CN103732062A (zh) 2014-04-16
PH12013502443A1 (en) 2019-03-22
MX2013013781A (es) 2014-01-08
PE20141316A1 (es) 2014-10-01
IL229448A0 (en) 2014-01-30
CL2013003358A1 (es) 2014-08-01
EP2713724A4 (en) 2015-03-11
EP2713724A1 (en) 2014-04-09
EA201391578A1 (ru) 2014-05-30
SG195049A1 (en) 2013-12-30
ECSP13013117A (es) 2014-06-30
KR20140036257A (ko) 2014-03-25
US20140163100A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
CO6811862A2 (es) Métodos para tratar esclerosis múltiple y preservar y/o aumentar el contenido de mielina
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
ES2579990T8 (es) Métodos y composiciones para tratar el síndrome metabólico
BR112014006324A2 (pt) método para tratar hcv
CL2015000450A1 (es) Métodos y composiciones para el tratamiento de una afección genética
CO6791602A2 (es) Métodos y sistemas para el tratamiento de pozos
BR112013029813A2 (pt) métodos e dispositivos para distribuição de conteúdo
CO7020865A2 (es) Microorganismos y métodos para producir alquenos
CO6970603A2 (es) Composiciones y métodos para tratar el virus de la hepatitis c
BR112015002704A2 (pt) superfícies sólidas e tratamentos antimicrobianos e processos para preparar os mesmos
BR112014009528A2 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112013033720A2 (pt) método para tratar eczema
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
PT2739268T (pt) Método e formulação para inalação
BR112014010450A2 (pt) composição e método
PL2704737T3 (pl) Terapeutyczne kompozycje nukleaz i sposoby
IL231061A0 (en) Antibacterial compounds and methods for use
BR112014009785A2 (pt) método para tratar ou reduzir efp
BR112014006291A2 (pt) composição e utilização da composição
BR112013022254A2 (pt) método e disposição para gerar oxigênio
BR112013008528A2 (pt) métodos para tratar psoríase
FR2979632B1 (fr) Additifs di-fonctionnels anti-depots et anti-corrosion
CO6801728A2 (es) Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis
BR112014004294A2 (pt) anestésico para peixes e método

Legal Events

Date Code Title Description
FC Application refused